| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net (distribution) contribution to noncontrolling interest | - | - | - | 0 |
| Cash paid for contingent consideration | 141,300 | - | - | - |
| Other | 6,300 | 100 | 1,300 | -6,600 |
| Net cash flow provided by (used in) financing activities | -164,900 | -34,700 | -23,000 | -691,400 |
| Net increase (decrease) in cash and cash equivalents | 1,388,400 | 281,200 | 189,000 | 642,600 |
| Effect of exchange rate changes on cash | 99,400 | 102,600 | 34,300 | 6,700 |
| Cash and cash equivalents at beginning of period | 2,375,000 | 2,375,000 | 2,375,000 | 1,049,900 |
| Cash and cash equivalents at end of period | 3,862,800 | 2,758,800 | 2,598,300 | 1,699,200 |
BIOGEN INC. (BIIB)
BIOGEN INC. (BIIB)